Hira Rizvi
A5005948108- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Gene expression and cancer classification
- DNA and Nucleic Acid Chemistry
- Molecular Biology Techniques and Applications
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- RNA modifications and cancer
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Chromatin Remodeling and Cancer
- Multiple and Secondary Primary Cancers
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Mechanisms of cancer metastasis
- Genomics and Rare Diseases
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer therapeutics and mechanisms
Memorial Sloan Kettering Cancer Center
2017-2025
AstraZeneca (United States)
2022-2024
Kettering University
2019-2023
New Cross Hospital
2023
The Royal Wolverhampton NHS Trust
2023
AstraZeneca (United Kingdom)
2023
Cornell University
2018-2022
Center for Cancer Research
2021
Beth Israel Deaconess Medical Center
2020
Harvard University
2020
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be attributed abnormal gut microbiome composition. Antibiotics inhibited benefit patients with advanced cancer. Fecal microbiota transplantation (FMT) from who responded into germ-free or antibiotic-treated mice ameliorated antitumor effects PD-1 blockade, whereas FMT nonresponding failed do so....
Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine efficacy PD-1 inhibitors these subgroups. Objective response rates to blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) (P < 0.001) Stand Up To Cancer (SU2C) cohort (174 patients) with LUAC patients treated nivolumab CheckMate-057 phase III...
Purpose Treatment of advanced non-small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset patients. Clinically available tools to optimize use ICIs understand the molecular determinants response are needed. Targeted next-generation sequencing (NGS) increasingly routine, but its role identifying predictors not known. Methods Detailed clinical annotation data were collected for patients treated anti-programmed...
Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. Methods Patients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb were identified at two institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, Melanoma...
Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing examine non-small-cell cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutation burden (TMB) predicted improved objective response, durable benefit, and progression-free survival. TMB was independent PD-L1 expression the strongest feature associated efficacy multivariable analysis....
Treatment with programmed cell death-1 or death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients lung cancer. The immunosuppressive effect of corticosteroids may reduce efficacy PD-(L)1 blockade. On-treatment treatment immune-related adverse events do not seem to affect efficacy, but the potential impact baseline at time initiation unknown. Clinical trials typically excluded who received corticosteroids, which led us use real-world data examine initiation.
The composition of gut microbiota affects antitumor immune responses, preclinical and clinical outcome following checkpoint inhibitors (ICI) in cancer. Antibiotics (ATB) alter diversity leading to dysbiosis, which may affect effectiveness ICI.We examined patients with advanced renal cell carcinoma (RCC) non-small-cell lung cancer (NSCLC) treated anti-programmed death ligand-1 mAb monotherapy or combination at two academic institutions. Those receiving ATB within 30 days beginning ICI were...
BackgroundAlthough EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some do respond these therapies; however, there is a lack of understanding the characteristics lung responsive blockade.Patients and methodsWe retrospectively analyzed de-identified clinical molecular data on 171 cases treated with inhibitors from Yale Cancer Center, Memorial Sloan Kettering University California Los Angeles, Dana Farber Institute. A separate cohort 383 cancer sequencing...
Purpose Although programmed death (PD)-1 pathway inhibitors are now used in nearly all patients with advanced non-small-cell lung cancer (NSCLC), the large number of NSCLC and concurrent autoimmune disease (AID) have been universally excluded from immunotherapy clinical trials. Therefore, safety PD-1 PD-ligand 1 (PD-L1) underlying AID is currently unknown. Methods As part a multi-institutional effort, we retrospectively collected clinicopathologic data history who received monotherapy either...
Considering retreatment following recovery from an immune-related adverse event (irAE) is a common clinical scenario, but the safety and benefit of unknown. We identified patients with advanced non-small cell lung cancer (NSCLC) treated anti-PD-(L)1 who had treatment held due to irAEs divided them into two groups: those retreated (retreatment cohort) or stopped (discontinuation cohort). Out 482 NSCLC anti-PD-(L)1, 68 (14%) developed serious irAE requiring interruption. Of these, 38 (56%)...
Abstract Purpose: Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint blockade (ICB). The impact TMB on outcomes with targeted therapies has not been explored. Experimental Design: We identified all patients metastatic EGFR exon19del or L858R-mutant lung cancers treated first/second-generation tyrosine kinase inhibitors (TKIs) pretreatment next-generation sequencing data (MSK-IMPACT assay). effect time-to-treatment discontinuation (TTD) and overall survival (OS) were...
BackgroundIn non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment the PD-1 inhibitor pembrolizumab improves survival compared platinum-doublet chemotherapy. Whether higher PD-L1 levels within range 50%–100% predict for even greater benefit to is currently unknown.Patients and methodsIn this multicenter retrospective analysis, we analyzed impact overall response rate (ORR), median progression-free (mPFS), (mOS) in patients...
Importance Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is lack consensus about the optimal TMB threshold that best discriminates improved outcomes immune checkpoint inhibitor therapy among patients with non–small cell lung cancer (NSCLC). Objectives To determine association between increasing levels and across clinically relevant programmed death ligand–1 (PD-L1) NSCLC. Design, Setting, Participants...
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer (NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we show the capacity of integrating medical imaging, histopathologic and genomic features predict immunotherapy response using a cohort 247 NSCLC multimodal baseline data obtained during diagnostic clinical workup, including computed tomography scan images, digitized programmed death ligand-1 immunohistochemistry...
mutations are among the most common recurrent alterations in non-small cell lung cancer (NSCLC), but relationship to other genomic abnormalities and clinical impact has not been established.
Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here first joint analysis Stand Up Cancer-Mark Foundation cohort, a resource whole exome and/or RNA sequencing from 393 patients with NSCLC treated anti-PD-(L)1 therapy, along matched clinical annotation. We identify number associations between and outcome,...